» Articles » PMID: 14734444

A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2004 Jan 22
PMID 14734444
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was to conduct a systematic review, and where possible meta-analyses, of molecular and biological tumor markers described in neuroblastoma, and to establish an evidence-based perspective on their clinical value for the screening, diagnosis, prognosis, and monitoring of patients.

Experimental Design: A well-defined, reproducible search strategy was used to identify the relevant literature from 1966 to February 2000.

Results: A total of 428 papers studying the use of 195 different tumor markers in neuroblastoma were identified. Small sample sizes, poor statistical reporting, large heterogeneity across studies (e.g., in cutoff levels), and publication bias limited meta-analysis to the area of prognosis only; MYCN, chromosome 1p, DNA index, vanillylmandelic acid:homovanillic acid ratio, CD44, Trk-A, neuron-specific enolase, lactate dehydrogenase, ferritin, and multidrug resistance were all identified as potentially important prognostic tools.

Conclusions: This systematic review forms a knowledge base of the tumor markers studied thus far in neuroblastoma, and has identified some of the most important prognostic markers, which should be considered in future research and treatment strategies. Importantly, the review has also highlighted some general problems across primary tumor marker studies, in particular poor and heterogeneous reporting. These need to be addressed to allow better clinical interpretation and enable more appropriate evidence-based reviews in the future. In particular, collaboration of cancer research groups is needed to enable bigger sample sizes, standardize methods of analysis and reporting, and facilitate the pooling of individual patient data.

Citing Articles

Effect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China.

Luo Z, Fan L, Guo W, Yang J, Li Z, Huang Y World J Stem Cells. 2025; 17(2):100621.

PMID: 40061267 PMC: 11885945. DOI: 10.4252/wjsc.v17.i2.100621.


Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.

Vercouillie N, Ren Z, Terras E, Lammens T Int J Mol Sci. 2024; 25(11).

PMID: 38891878 PMC: 11171840. DOI: 10.3390/ijms25115690.


Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.

Nakatani N, Win K, Mon C, Fujikawa T, Uemura S, Saito A Biology (Basel). 2024; 13(5).

PMID: 38785826 PMC: 11117621. DOI: 10.3390/biology13050345.


Multifunctional roles of γ-enolase in the central nervous system: more than a neuronal marker.

Horvat S, Kos J, Pislar A Cell Biosci. 2024; 14(1):61.

PMID: 38735971 PMC: 11089681. DOI: 10.1186/s13578-024-01240-6.


Tumour Hidden behind Thoracic Spine Pain: A Rare Case of Neuroblastoma in a Young Mother-A Case Report.

Passudetti V, De Leo L, Maselli F, Pellegrino R, Brindisino F Int J Environ Res Public Health. 2022; 19(20).

PMID: 36294024 PMC: 9602929. DOI: 10.3390/ijerph192013448.